HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. Issue 1 (27th March 2022)

• Record Type: Journal Article
• Authors: Huang, Yue; Yu, Qin; Yin, Elaine Tan Su; Wei, Guoqing; Wu, Wenjun; Chang, Alex H.; Huang, He; Hu, Yongxian
• Other Names: Huang He guestEditor.
• Is Part Of: Immunomedicine. Volume 2:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-27
• Subjects: acute lymphoblastic leukemia -- allogeneic chimeric antigen receptor T cells -- central nervous system leukemia -- cytokine release syndrome -- HLA‐matched; 616.079
• DOI: 10.1002/imed.1032
• Languages: English
• ISSNs: 2510-5345

Abstract

Abstract: The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with high tumor burden and prior tumor‐reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor‐derived HLA‐matched allogeneic CAR‐T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR‐T therapy.